share_log

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K:重大事件
美股sec公告 ·  07/30 16:06
Moomoo AI 已提取核心訊息
Avalo Therapeutics, Inc. has been granted a 180-day extension by the Nasdaq Stock Market LLC to meet the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The extension, which lasts until November 18, 2024, follows the company's non-compliance notice received on May 20, 2024, due to its reported negative stockholders' equity of $112.5 million as of March 31, 2024. Avalo Therapeutics had submitted a plan of compliance to Nasdaq's Listing Qualifications Department in response to the notice. While the extension provides additional time for Avalo Therapeutics to regain compliance, there is no guarantee that the company will meet the Nasdaq's Listing Rule by the new deadline.
Avalo Therapeutics, Inc. has been granted a 180-day extension by the Nasdaq Stock Market LLC to meet the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The extension, which lasts until November 18, 2024, follows the company's non-compliance notice received on May 20, 2024, due to its reported negative stockholders' equity of $112.5 million as of March 31, 2024. Avalo Therapeutics had submitted a plan of compliance to Nasdaq's Listing Qualifications Department in response to the notice. While the extension provides additional time for Avalo Therapeutics to regain compliance, there is no guarantee that the company will meet the Nasdaq's Listing Rule by the new deadline.
Avalo Therapeutics, Inc.已獲得納斯達克證券市場有限公司的180天延期,以滿足在納斯達克資本市場上繼續上市的最低股東權益要求。該延期將持續到2024年11月18日,這是因爲該公司於2024年3月31日報告的負股東權益11250萬美元導致其於2024年5月20日收到不符合通知。Avalo Therapeutics已向納斯達克的上市資格部門提交了符合要求計劃的響應通知。儘管該延期爲Avalo Therapeutics提供了額外時間來恢復符合要求,但無法保證該公司將在新的最後期限前符合納斯達克的上市規則。
Avalo Therapeutics, Inc.已獲得納斯達克證券市場有限公司的180天延期,以滿足在納斯達克資本市場上繼續上市的最低股東權益要求。該延期將持續到2024年11月18日,這是因爲該公司於2024年3月31日報告的負股東權益11250萬美元導致其於2024年5月20日收到不符合通知。Avalo Therapeutics已向納斯達克的上市資格部門提交了符合要求計劃的響應通知。儘管該延期爲Avalo Therapeutics提供了額外時間來恢復符合要求,但無法保證該公司將在新的最後期限前符合納斯達克的上市規則。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息